Scarica l'app Stockscreener
702.75
3.11%
-22.59
Pre-mercato:
722.01
19.26
+2.74%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$725.34
Aprire:
$727.81
Volume 24 ore:
1.37M
Relative Volume:
1.29
Capitalizzazione di mercato:
$73.21B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
16.82
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
+3.08%
1M Prestazione:
+21.57%
6M Prestazione:
+17.80%
1 anno Prestazione:
-5.62%
Intervallo 1D:
$702.63
$727.81
Intervallo di 1 settimana:
$679.93
$727.97
Portata 52W:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
702.75 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.03 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.76 | 61.08B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.59 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.56 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Stocks to Watch : Nvidia, Kulicke & Soffa, Regeneron - MarketScreener
Regeneron (REGN) Gains FDA Approval for Eylea HD Injection - GuruFocus
Regeneron Gets FDA Approval for Eylea to Treat Macular Edema - MarketScreener
FDA Approves Eylea HD Injection from Regeneron (REGN) for Eye Conditions - GuruFocus
FDA approves EYLEA HD for retinal vein occlusion with extended dosing - Investing.com Canada
Regeneron stock rises as EYLEA HD gets FDA approval for new indication - Investing.com Canada
Regeneron Announces FDA Approval of EYLEA HD® for Retinal Vein Occlusion with New Dosing Options - Quiver Quantitative
Regeneron (NASDAQ: REGN) secures FDA approval for EYLEA HD in RVO with 8-week option and monthly dosing - Stock Titan
Why analysts raise outlook for Regeneron Pharmaceuticals Inc. (RGO) stockJuly 2025 Highlights & Free Real-Time Market Sentiment Alerts - newser.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected - simplywall.st
Why Regeneron Pharmaceuticals Inc. (RGO) stock is favored by hedge funds2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
How currency fluctuations impact Regeneron Pharmaceuticals Inc. stockMarket Volume Summary & Reliable Momentum Entry Alerts - newser.com
Regeneron (REGN) Gains EU Approval for Expanded Use of Libtayo - GuruFocus
Regeneron gets EU nod for expanded approval of Libtayo (REGN:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals Gets European Commission's Approval for Expanded Indication for Libtayo - MarketScreener
European Commission Approves the Pd-1 Inhibitor Libtayo of Regeneron Pharmaceuticals, Inc - MarketScreener
Can a trend reversal in Regeneron Pharmaceuticals Inc. lead to recoveryWeekly Investment Summary & Low Volatility Stock Recommendations - newser.com
REGN: European Approval for Regeneron's Libtayo in Skin Cancer T - GuruFocus
Regeneron (REGN) EC Approves Libtayo as First Adjuvant CSCC Immunotherapy, 68% Risk Cut - Stock Titan
How Regeneron Pharmaceuticals Inc. stock responds to policy changes2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
United States Bispecific T-cell Engagers (BiTEs) Market Size, - openPR.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Raiffeisen Bank International AG - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by ARS Investment Partners LLC - MarketBeat
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shiftsMarket Weekly Review & Weekly High Return Forecasts - newser.com
How strong is Regeneron Pharmaceuticals Inc. stock balance sheetWeekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Can Regeneron Pharmaceuticals Inc. stock weather global recessionStop Loss & Growth Focused Investment Plans - newser.com
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - newser.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Citigroup Inc. - MarketBeat
Feds Look to 'False Certification' FCA Strategy - Law360
Semanteon Capital Management LP Sells 1,123 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How Regeneron’s FDA Approvals and Recent Price Jump Impact Its 2025 Valuation - simplywall.st
Universal Beteiligungs und Servicegesellschaft mbH Has $55.94 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Ex-Dividend Reminder: CenterPoint Energy, Regeneron Pharmaceuticals and LeMaitre Vascular - Nasdaq
SG Americas Securities LLC Has $8.42 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What data driven models say about Regeneron Pharmaceuticals Inc.’s futureJuly 2025 Sector Moves & Fast Entry and Exit Trade Plans - newser.com
PNC Financial Services Group Inc. Cuts Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bedell Frazier Investment Counselling LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Drug-maker Regeneron plans $2B facility upstate, following Trump’s pharma tariffs - Crain's New York Business
Citizens Financial Group Inc. RI Acquires 1,871 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds? - Finviz
How robust is Regeneron Pharmaceuticals Inc. (RGO) stock financial positionWeekly Trend Summary & Weekly Breakout Watchlists - newser.com
REGN: Eylea HD growth, label updates, and strategic capital deployment drive future outlook - TradingView
Chronic Obstructive Pulmonary Disease Market Forecast - openPR.com
Regeneron at Jefferies London: Strategic Growth and Challenges - Investing.com
Regeneron at Wolfe Research Conference: Oncology Pipeline Insights - Investing.com
Westwood Holdings Group Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Persistent Asset Partners Ltd Sells 5,625 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.33%
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):